This book provides a practical, comprehensive, state-of-the-art review of bladder cancer. A valuable resource for anyone with an interest in urothelial tumors, this text brings together a multidisciplinary team of experts who have distilled their vast years of experience and knowledge into a concise, easy to digest format. Topics covered range from importance of a pattern recognition in diagnosis and pathologic evaluation to ‘how I do it’ tips on patient selection for appropriate therapies such as chemotherapy, immunotherapy, surgery and radiation. Bridging the gap between a traditional textbook and hands-on experience, this book provides a practical guide to managing day-to-day issues and challenges and brings an algorithmic approach to avoid common pitfalls. Bladder Cancer: A Practical Guide provides a concise yet comprehensive summary of the current status of the field of bladder cancer treatment, guiding patient management and stimulating investigative efforts.

This book provides a systematic review of the management and treatment of this disease. The concise and highly structured chapters feature essential background knowledge and commentary on recent advances within each step of a range of patient pathways. Management of Muscle Invasive Bladder Cancer provides a framework for patients’ care based on the research, as well as practically and clinically oriented guidelines. This book is relevant to trainees and practicing urologists and oncologists, in addition to medical professionals involved in the treatment of bladder cancer.

Bladder Cancer: Diagnosis and Clinical Management is a 100% clinically-focused guide to bladder cancer, providing practical, modern and evidence-based guidance to the latest in diagnosis and management of the condition. It differs from other books in its complete clinical focus as opposed to a heavy analysis of pathogenesis or basic science. As a result, practicing urologists and oncologists in the clinical setting will find it an essential resource to consult. In addition to the latest in diagnostic tools and imaging methods, core focus is on the management of each form of cancer at its various stages with up to date genomic data and targeted therapies. Both drug therapies and the range of surgical options are covered, ensuring that this is the perfect tool for clinicians to consult when considering which type of management program is appropriate for each individual patient. A key addition is the final section dedicated to optimizing health care delivery, featuring chapters on highly topical issues such as quality of life, patient advocacy and surgical education. Full color throughout, and packed with excellent images, each chapter contains concise and didactic practical tips and tricks to enrich the reading experience, in addition to management algorithms and the very latest guidelines from the ASCO, AUA, ESMO and EAU concerning clinical management of bladder cancer.

Rare Genitourinary Tumors offers the reader an up-to-date discussion of the less common neoplasms affecting the urinary tract and reproductive organs. Each authoritative chapter provides and in-depth discussion that is frequently not found in other urologic oncology textbooks. A valuable reference for urologists, oncologists, and those in specialty training, this volume provides ready access to information on etiology, incidence, risk factors, diagnosis, prognosis, insights from molecular pathology and, where applicable, data from clinical trials. The practical treatment guidelines included for each tumor type are written by experts and fully referenced.

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

Michael J. Droller, MD and a panel of experienced clinicians bring their strong background in clinical research to bear on the assessment and management of bladder cancer. Their comprehensive discussion summarizes the state-of-the-art in diagnosis and treatment, based on the latest understanding of bladder cancer's epidemiology, carcinogenesis, and tumor markers. Topics of particular interest include the role of genetics and molecular biology in evaluating bladder cancer clinically, the evaluation of the results of systemic treatment in advanced disease, the current status of tumor markers in bladder cancer, and the means for further study in their applicability. Insightful and evidenced-based, Bladder Cancer: Current Diagnosis and Treatment provides active clinicians and clinical investigators with not only a critical survey of the rapidly expanding research in the area, but also a state-of-the-art tutorial on today's optimal assessment and treatment of bladder cancer.

The authors aim to provide essential information on various clinical cases on urological cancers. The main messages are well referenced and the texts phrasing is written in a simple and user-friendly style. The book also contains summarizing tables and high quality original pictures. Several expert panels (American Urologists Association, European Association of Urologists, Association Française des Urologues, etc) are proposing guidelines aiming at providing detailed recommendations to the Urologists facing difficult urological scenarios and no significant discordance exist between them since they are all based on the existing published studies dealing with different aspects of the urological cancers.